Filter
545
Featured
Recommendations
103
New Publications
117
Language
Document type
No document type
212
Guidelines
167
Manuals
31
Studies & Reports
31
Strategic & Response Plan
24
Fact sheets
23
Training Material
15
Resource Platforms
13
Online Courses
13
Infographics
8
Situation Updates
4
Videos
2
App
1
Countries / Regions
Global
32
Latin America and the Carribbean
14
India
8
Ukraine
8
Africa
8
Russia
6
Congo, Democratic Republic of
5
Brazil
5
Middle East and North Africa
5
Mozambique
4
South–East Asia Region
4
Western and Central Europe
4
Haiti
3
Germany
3
South Africa
3
Yemen
3
East and Southern Africa
3
West and Central Africa
3
Eastern Europe
3
Nigeria
2
Zimbabwe
2
Pakistan
2
Zambia
2
Kenya
2
Bangladesh
2
Guinea
1
Sierra Leone
1
Liberia
1
Senegal
1
Somalia
1
Nepal
1
Afghanistan
1
Syria
1
Argentina
1
Colombia
1
Ecuador
1
Angola
1
Guatemala
1
Sri Lanka
1
Chile
1
Western Pacific Region
1
Eastern Europe and Central Asia
1
Asia
1
Bhutan
1
Authors & Publishers
Publication Years
Toolboxes
TB
84
Rapid Response
81
HIV
53
Malaria
30
Cholera
25
Refugee
19
COVID-19
13
Caregiver
13
2.0 Rapid Response
12
Mental Health
8
Polio
7
Ebola & Marburg
6
Conflict
6
Natural Hazards
5
NTDs
3
AMR
2
Planetary Health
2
Zika
1
Pharmacy
1
Health Financing Toolbox
1
Epidemics of infectious diseases are occurring more often, and spreading faster and further than ever, in many different regions of the world. The background factors of this threat are biological, environmental and lifestyle changes, among others. A potentially fatal combination of newly-discovered
...
A practical tool to help health workers in the clinical and operational management of multidrug-resistant tuberculosis with special focus on the introduction, implementation and management of the nine-month treatment regimen.
Evidence-to-Decision and Grade tables
The scope of this PPC document is to serve as a guide to address the unmet public health need for a PPE system that protects the HW-F in tropical climate
s while caring for patients and providing heavy duty essential health services.
The characteristics described in this guidance are targeted fo
...
Prise en charge d’une épidémie de choléra
recommended
Guide pratique à l’usage des médecins, infirmiers, techniciens de laboratoire, auxiliaires de santé, techniciens sanitaires et logisticiens.
Le document est un guide complet pour la gestion des épidémies de choléra, fournissant des protocoles détaillés pour la prévention, l’investigat
...
The EYE strategy is a comprehensive and long-term strategy built on lessons learned that aims at ending yellow fever epidemics by 2026, and consists of three strategic objectives:
protect at-risk populations;
prevent international spread; and
contain outbreaks rapidly.
Latent Tuberculosis Infection : Updated and consolidated guidelines for programmatic management
recommended
The consolidated guidelines are expected to provide the basis and rationale for the development of national guidelines for LTBI management, adapted to the national and local epidemiology of TB, the availability of resources, the health infrastructure and other national and local determinants. The gu
...
A practical tool to help health workers in the clinical and operational management of multidrug-resistant tuberculosis with special focus on the introduction, implementation and management of the nine-month treatment regimen.
Management of a cholera epidemic
recommended
Practical guide for doctors, nurses,laboratory technicians, medical auxiliaries,water and sanitation specialists and logisticians.
The document is a comprehensive guide for managing cholera epidemics, providing detailed protocols for prevention, outbreak investigation, treatment, and control mea
...
Translated and adapted from the original English Antiretroviral drugs chart by the East Europe and Central Asia Union of People Living with HIV (ECUO). This resource shows drugs currently available in the Eastern Europe and Central Asia area.
Last update Oct. 2018
The new, all oral, 20-month MDR-TB regimens range from US $1,600* (using bedaquiline and linezolid for 6 months and levofloxacin as the fluoroquinolone) to US $2,100* (using linezolid for 12 months and moxifloxacin as the fluoroquinolone.
Assurer des prestations optimales dans la chaîne de soins destinés aux patients tuberculeux
Deuxième édition - Juin 2018
The new WHO recommendations for the treatment of isoniazid-resistant, rifampicin-susceptible TB are based upon a review of evidence from patients treated with such regimens by a Guideline Development Group in conformity with WHO requirements for evidence-based policies.
